XML 36 R17.htm IDEA: XBRL DOCUMENT

ShareBased Compensation

9 Months Ended

Sep. 30, 2020

Note 10. Share-Based Compensation

Equity Plans

On June 20, 2017, the stockholders of the Company approved the ChromaDex Corporation 2017 Equity Incentive Plan (the "2017 Plan"). The Company's Board of Directors amended the 2017 Plan in January 2018 and the stockholders of the Company approved amendments to the 2017 Plan in June 2018 and June 2020. The 2017 Plan is the successor to the ChromaDex Corporation Second Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). As of September 30, 2020, under the 2017 Plan, the Company is authorized to issue shares subject to awards that total no more than the sum of (i) 14,500,000 new shares, (ii) approximately 384,000 unallocated shares remaining available for the grant of new awards under the 2007 Plan, (iii) any returning shares from the 2007 Plan or the 2017 Plan, such as forfeited, cancelled, or expired shares and (iv) 500,000 shares pursuant to an inducement award. The remaining number of shares available for issuance under the 2017 Plan totaled approximately 6.7 million shares at September 30, 2020.

General Vesting Conditions

The stock option awards generally vest ratably over a three-year period following grant date after a passage of time. However, some stock option awards are market or performance based and vest based on certain triggering events established by the Compensation Committee of the Board of Directors.

The fair value of the Company’s stock options that are not market based is estimated at the date of grant using the Black-Scholes option pricing model. The table below outlines the weighted average assumptions for options granted during the nine months ended September 30, 2020.

Nine months Ended September 30, 2020
Expected term	6		years
Expected volatility		66	%
Risk-free rate		1	%
Expected dividends		0	%

The following table summarizes performance based stock options activity at September 30, 2020 and changes during the nine months then ended (in thousands except per share data and remaining contractual term):

				Weighted Average
						Remaining				Aggregate
	Number of			Exercise		Contractual		Fair		Intrinsic
	Shares			Price		Term (Years)		Value		Value
Outstanding at Dec. 31, 2019		42		$	1.89		3.1

Options Granted		164			4.34		4.0	$	2.26
Options Exercised		(42	)		1.89					$	100
Options Forfeited		(83	)		4.34
Outstanding at Sep. 30, 2020		81		$	4.34		3.3			$	0	*

Exercisable at Sep. 30, 2020		81		$	4.34		3.3			$	0	*